MedPath

Local Anesthetic Treatments for Overactive Bladder

Phase 3
Terminated
Conditions
Overactive Bladder
Interventions
Registration Number
NCT00427648
Lead Sponsor
Frank Tu
Brief Summary

The purpose of this study is to determine whether alkalized lidocaine instilled into the bladder is effective in the treatment of overactive bladder (OAB).

Detailed Description

Existing first-line treatments for overactive bladder are limited by requirements for chronic dosing and associated systemic side effects. Small case series suggest that bladder instillation of lidocaine may be effective in downregulating the afferent neuronal activity of a sensitized bladder, leading to elevation of the urge sensory threshold and decreasing detrusor activity. However, neither the effectiveness over placebo nor the durability of the response has been previously investigated.

Comparison(s): We propose a randomized, prospective double-blinded controlled trial to determine if a three-week trial of intravesical alkalized lidocaine instillation decreases symptoms of overactive bladder more than instillation of normal saline using a validated outcome instrument, the OAB-q.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
22
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1alkalinized xylocainexylocaine
2placebonormal saline
Primary Outcome Measures
NameTimeMethod
Median Number of Daily Voiding Episodes (by 3-day Voiding Diary) at Six Weeks.6 weeks
Secondary Outcome Measures
NameTimeMethod
OAB-q (Symptom Scale) at 6 Weeks6 weeks

OAB-q SS is a 7 item overactive bladder symptom bother sub scale, ranging from 0-100, higher scores mean worse outcome for bother

Cystometric Assessment of Maximal Bladder Capacity at 6 Weeks Only.6 weeks

This is based on retrograde infusion of sterile water into the bladder using a catheter, the maximum tolerated volume serving to define how much distension a woman can tolerate.

Median Number of Daily Voiding Episodes at 12 Months.12 months
SF-12 Physical at 6 Weeks6 weeks

SF-12 physical is an abbreviated version of the SF-36 a widely used, general health care quality of life instrument. Scores range from 0-100, and higher scores are better outcomes.

Global Assessment of Change - Frequency at 6 Weeks6 weeks

This is patient overall assessment of change in overactive bladder symptoms after treatment. 0% is no change, 100% is total resolution of symptoms

Average Weekly NRS for Frequency at 6 Weeks6 weeks

NRS - numerical rating scale, 0-10 is the range, and higher scores are worse frequency

Trial Locations

Locations (1)

NorthShore University HealthSystem

🇺🇸

Park City, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath